Bioxcel therapeutics announces first patients dosed in serenity iii phase 3 trial for acute treatment of agitation in adults with bipolar i or ii disorder or schizophrenia

Serenity iii will evaluate the efficacy and safety of bxcl501 for at-home use

BTAI Ratings Summary

BTAI Quant Ranking